Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
VB-119 by Acelyrin for Focal Segmental Glomerulosclerosis (FSGS): Likelihood of Approval
VB-119 is under clinical development by Acelyrin and currently in Phase II for Focal Segmental Glomerulosclerosis (FSGS). According to GlobalData,...